Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, providing a potential pill-based alternative to Novo Nordisk's Wegovy and Eli Lilly's Zepbound weight loss injections. "We are fast-tracking the clinical development of our obesity portfolio with the aim to bring ...